Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Group 1 - Outlook Therapeutics, Inc. has received regulatory approval in the European Union and the United Kingdom for the first authorized ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (wet AMD) [1][4] - The company participated in the 2nd Annual Chardan Virtual Ophthalmology Conference, focusing on age-related macular degeneration and diabetes-related ocular diseases, alongside seven other companies [2] - The commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK is expected in the first half of calendar 2025 [4] Group 2 - ONS-5010/LYTENAVA™ is currently investigational in the United States and is undergoing a non-inferiority study for wet AMD treatment [4] - If the ongoing study is successful, the data may support a resubmission of a Biologics License Application (BLA) to the FDA [4] - If approved in the United States, ONS-5010/LYTENAVA™ would be the first approved ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [4]